{{Drugbox
| IUPAC_name = 6-Fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]imidazo[1,2-a]pyridine
| image = Dipraglurant.svg
| CAS_number = 872363-17-2
| ATC_prefix = None
| ATC_suffix= 
| PubChem= 44557636
| DrugBank= 
| ChemSpiderID= 25069676
| chemical_formula =
| C=16 | H=12 | F=1 | N=3
| molecular_weight  = 265.285 g/mol
| smiles= c1ccnc(c1)C#CCCc2cn3cc(ccc3n2)F
| StdInChI= 1S/C16H12FN3/c17-13-8-9-16-19-15(12-20(16)11-13)7-2-1-5-14-6-3-4-10-18-14/h3-4,6,8-12H,2,7H2
| StdInChIKey= LZXMUJCJAWVHPZ-UHFFFAOYSA-N
| bioavailability= 
| protein_bound= 
| metabolism= 
| elimination_half-life = 
| excretion= 
| pregnancy_AU=  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US=  <!-- A / B/ C / D / X -->
| pregnancy_category=  
| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status= 
| routes_of_administration = 
}}

'''Dipraglurant''' ([[International Nonproprietary Name|INN]]) (code name '''ADX-48621''') is a [[negative allosteric modulator]] of the [[mGlu5 receptor|mGlu<sub>5</sub> receptor]] which is under development by [[Addex Therapeutics]] for the treatment of [[Parkinson's disease]] [[levodopa-induced dyskinesia]] (PD-LID).<ref name="MartinezGil2013">{{cite book|author1=Ana Martinez|author2=Carmen Gil|title=Emerging Drugs and Targets for Parkinson's Disease|url=https://books.google.com/books?id=g3_8KlQvenAC&pg=PA255|date=29 July 2013|publisher=Royal Society of Chemistry|isbn=978-1-84973-617-6|pages=255–}}</ref><ref name="Macor2012">{{cite book|author=John E. Macor|title=Annual Reports in Medicinal Chemistry|url=https://books.google.com/books?id=xpe9Mk50BGsC&pg=PA83|year=2012|publisher=Academic Press|isbn=978-0-12-396492-2|pages=83–}}</ref><ref name="FoxBrotchie2014">{{cite book|author1=Susan H. Fox|author2=Jonathan M. Brotchie|title=Levodopa-Induced Dyskinesia in Parkinson's Disease|url=https://books.google.com/books?id=ME69BAAAQBAJ&pg=PA323|date=8 October 2014|publisher=Springer|isbn=978-1-4471-6503-3|pages=323–}}</ref> As of 2014, it is in [[Phases of clinical research|phase II]] [[clinical trial]]s for this indication.<ref name="MartinezGil2013" /> Addex Therapeutics is also investigating an [[extended-release formulation]] of dipraglurant for the treatment of non-[[parkinsonian]] [[dystonia]].<ref name="Addex2014">{{cite web | url = http://www.addextherapeutics.com/rd/pipeline/dipra-er/ | title = Dipraglurant-ER for dystonia | author = Addex Therapeutics}}</ref>

==See also==
* [[Basimglurant]]
* [[Fenobam]]
* [[Mavoglurant]]
* [[Raseglurant]]

==References==
{{Reflist|2}}

==External links==
* [http://www.addextherapeutics.com/rd/pipeline/dipra-ir/ Dipraglurant-IR for Parkinson's disease levodopa-induced dyskinesia - Addex Therapeutics]
* [http://www.addextherapeutics.com/rd/pipeline/dipra-er/ Dipraglurant-ER for dystonia - Addex Therapeutics]

{{Metabotropic glutamate receptor modulators}}

[[Category:Imidazopyridines]]
[[Category:MGlu5 receptor antagonists]]
[[Category:Organofluorides]]
[[Category:Alkynes]]


{{nervous-system-drug-stub}}